Interpace Biosciences Reports Results for Quarter Ended March 31, 2026

What Happened
Interpace Biosciences, Inc. (IDXG) filed a Form 8-K reporting results of operations and financial condition for the quarter ended March 31, 2026. The company issued a press release on May 12, 2026 announcing those quarterly results; the full press release is attached to the 8-K as Exhibit 99.1 and is incorporated by reference. The 8-K was filed on May 14, 2026.

Key Details

• Filing: Form 8-K (Item 2.02) reporting results of operations and financial condition.
• Quarter covered: quarter ended March 31, 2026.
• Press release date: May 12, 2026; full text attached as Exhibit 99.1 to the 8-K.
• 8-K filing date: May 14, 2026.

Why It Matters
Quarterly results provide updated information on Interpace’s earnings, revenue, cash position and operational progress that can affect valuation and near-term trading. Retail investors should review the attached press release (Exhibit 99.1) and any accompanying financial statements or management commentary to see reported revenue, net income/loss, cash flow and any guidance or notable developments disclosed for the March 31, 2026 quarter.